MedTrace Logo

Retrospective Analysis of Colorectal Cancer Screening Results

NCT05374369 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 822

Last updated 2022-07-29

No results posted yet for this study

Summary

The purpose of this study is to retrospectively analyze colorectal cancer screening data of 40-74 year old population in Shipai Town, Dongguan City.

In this study, the data of SDC2 Gene Methylation Test and Fecal Immunochemistry Test (Q-FIT) were screened from about 11,000 subjects who participated in Colorectal Cancer Screening in Shipai Town People's Livelihood Project from May 2021 to May 2022. Data from 822 subjects with positive SDC2 Gene Methylation Test and/or positive Fecal Immunochemistry Test (Q-FIT) results and with colonoscopy and/or pathological results were selected for retrospective analysis.

This retrospective study evaluated the screening performance of SDC2 Gene Methylation Test and/or Fecal Immunochemistry Test (Q-FIT) for colorectal cancer using colonoscopy and/or pathological results as the clinical standard method.

Conditions

  • Colorectal Cancer
  • Advanced Adenocarcinoma
  • Hyperplastic Polyp
  • Colorectal Neoplasms
  • Digestive System Neoplasm
  • Neoplasms

Interventions

DIAGNOSTIC_TEST

SDC2 Gene Methylation Test and Q-FIT Test

Stool specimens were collected by the subjects for SDC2 Gene Methylation Test and Q-FIT Test

PROCEDURE

Colonoscopy and/or pathological examination

Subjects underwent colonoscopy and/or pathological examination.

Sponsors & Collaborators

  • Dongguan Shipai Hospital

    collaborator UNKNOWN

  • Creative Biosciences (Guangzhou) Co., Ltd.

    lead INDUSTRY

Principal Investigators

  • Zhi Zhang · Dongguan Shipai Hospital

Eligibility

Min Age
40 Years
Max Age
74 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-03-29
Primary Completion
2022-04-28
Completion
2022-04-28

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05374369 on ClinicalTrials.gov